Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report released on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and set a $5.00 price objective on shares of Minerva Neurosciences in a report on Wednesday, November 6th.

Minerva Neurosciences Trading Down 3.0 %

NASDAQ NERV opened at $2.26 on Friday. The business’s 50-day moving average price is $2.28 and its 200 day moving average price is $2.70. Minerva Neurosciences has a twelve month low of $2.06 and a twelve month high of $13.49. The company has a market capitalization of $15.80 million, a PE ratio of -5.14 and a beta of 0.11.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.